SITAMET - AVENIR 50 MG850 MG

Land: Israel

Sprache: Englisch

Quelle: Ministry of Health

Wirkstoff:

METFORMIN HYDROCHLORIDE; SITAGLIPTIN AS HYDROCHLORIDE MONOHYDRATE

Verfügbar ab:

BIOAVENIR LTD, ISRAEL

ATC-Code:

A10BD07

Darreichungsform:

FILM COATED TABLETS

Zusammensetzung:

METFORMIN HYDROCHLORIDE 850 MG; SITAGLIPTIN AS HYDROCHLORIDE MONOHYDRATE 50 MG

Verabreichungsweg:

PER OS

Verschreibungstyp:

Required

Hergestellt von:

HETERO LABS LIMITED, INDIA

Therapiebereich:

METFORMIN AND SITAGLIPTIN

Anwendungsgebiete:

Sitamet-Avenir is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. Important limitations of use: Sitamet-Avenir should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. Sitamet-Avenir has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitamet-Avenir.

Berechtigungsdatum:

2022-03-08

Gebrauchsinformation

PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
This medicine is dispensed with a doctor’s prescription only
SITAMET-AVENIR 50 MG/850 MG
FILM-COATED TABLETS
Each tablet contains:
sitagliptin
(as HCl monohydrate) 50 mg
metformin hydrochloride
850 mg
SITAMET-AVENIR 50 MG/1000 MG
FILM-COATED TABLETS
Each tablet contains:
sitagliptin
(as HCl monohydrate) 50 mg
metformin hydrochloride
1000 mg
Inactive ingredients and allergens: see section 2 sub-section
"Important information about some of this
medicine’s ingredients" and section 6 "Additional information".
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet contains concise
information about Sitamet-Avenir. If you have any further questions,
consult your doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even if it seems
to you that their medical condition is similar to yours.
This medicine is not intended for administration to children below the
age of 18 years.
1. WHAT IS SITAMET-AVENIR INTENDED FOR?
Along with recommended diet and exercise plan, Sitamet-Avenir is
intended to reduce blood sugar levels in
patients with type 2 diabetes.
THERAPEUTIC GROUP: Sitagliptin: DPP-4 enzyme inhibitor. Metformin:
biguanide.
Sitamet-Avenir is a tablet containing two active ingredients,
sitagliptin and metformin, which reduce the
blood sugar level.
Sitagliptin, which belongs to a class of medicines called DPP-4
inhibitors (dipeptidyl peptidase-4
inhibitors), and metformin, which belongs to the class of biguanide
medicines, act together to control blood
sugar levels in patients with type 2 diabetes, for whom this
combination is suitable.
2. BEFORE USING SITAMET-AVENIR
DO NOT USE SITAMET-AVENIR IF:
•
You are sensitive (allergic) to the active ingredients or to any of
the other ingredients in Sitamet-
Avenir (see section 6 "Additional information" for complete list of
the ingredients in Sitamet-Avenir).
Symptoms of a serious allergic reaction to S